DK2374461T3 - Piroxicam til profylaktisk og terapeutisk behandling af herpesinfektioner - Google Patents

Piroxicam til profylaktisk og terapeutisk behandling af herpesinfektioner Download PDF

Info

Publication number
DK2374461T3
DK2374461T3 DK11001816.5T DK11001816T DK2374461T3 DK 2374461 T3 DK2374461 T3 DK 2374461T3 DK 11001816 T DK11001816 T DK 11001816T DK 2374461 T3 DK2374461 T3 DK 2374461T3
Authority
DK
Denmark
Prior art keywords
agent
virus
prophylactic
herpes
therapeutic treatment
Prior art date
Application number
DK11001816.5T
Other languages
English (en)
Inventor
Jan Slomianny
Original Assignee
Hov Gmbh
Jan Slomianny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hov Gmbh, Jan Slomianny filed Critical Hov Gmbh
Application granted granted Critical
Publication of DK2374461T3 publication Critical patent/DK2374461T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

1. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner med en virus fra familien af herpesvirus, kendetegnet ved, at midlet indeholder piroxicam i en bæresubstans.
2. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner forårsaget af en virus af familien af herpesvirus ifølge krav 1, kendetegnet ved et indhold af piroxicam beliggende imellem 0,1 og 10 vægt-%.
3. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner forårsaget af en virus af familien af herpesvirus ifølge krav 2, kendetegnet ved et indhold af piroxicam, beliggende imellem 1 og 5 vægt-%.
4. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner forårsaget af en virus af familien af herpesvirus ifølge ethvert af de foregående krav, kendetegnet ved, at virusinfektionen er en infektion forårsaget af herpes simplex, især herpes labialis.
5. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner forårsaget af en virus af familien af herpesvirus ifølge ethvert af de foregående krav, til topisk indgivelse.
6. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner forårsaget af en virus af familien af herpesvirus ifølge krav 5, i form af en creme, salve, tinktur eller en gel.
7. Middel til anvendelse ved en profylaktisk og terapeutisk behandling af virusinfektioner forårsaget af en virus af familien af herpesvirus ifølge ethvert af kravene 1 til 4, til infusion eller injektion.
DK11001816.5T 2010-04-08 2011-03-04 Piroxicam til profylaktisk og terapeutisk behandling af herpesinfektioner DK2374461T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010014290A DE102010014290A1 (de) 2010-04-08 2010-04-08 Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen

Publications (1)

Publication Number Publication Date
DK2374461T3 true DK2374461T3 (da) 2017-02-06

Family

ID=43970974

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11001816.5T DK2374461T3 (da) 2010-04-08 2011-03-04 Piroxicam til profylaktisk og terapeutisk behandling af herpesinfektioner

Country Status (11)

Country Link
US (2) US20130190301A1 (da)
EP (1) EP2374461B1 (da)
JP (1) JP6158077B6 (da)
CN (1) CN103153312B (da)
CA (1) CA2795334C (da)
DE (1) DE102010014290A1 (da)
DK (1) DK2374461T3 (da)
ES (1) ES2612584T3 (da)
PL (1) PL2374461T3 (da)
RU (1) RU2555765C2 (da)
WO (1) WO2011124366A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010014290A1 (de) * 2010-04-08 2011-10-13 Hans Otto Meyer zu Spelbrink Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen
DE102013003756A1 (de) 2013-03-06 2014-09-11 DeaValorum UG (haftungsbeschränkt) Piroxicam zur prophylaktischen und therapeutischen Behandlung von CMV-Infektionen
DE102013014787A1 (de) 2013-09-09 2015-03-12 Dauphine UG (haftungsbeschränkt) Mittel zur prophylaktischen und therapeutischen Behandlung von EHV-Infektionen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
IT1216686B (it) * 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
IT1230922B (it) * 1989-06-23 1991-11-08 Giuseppe De Benedittis Composizione per il trattamento della nevralgia erpetica acuta e della nevralgia post erpetica
DK0453603T3 (da) * 1990-04-26 1993-11-22 Com Pharm Arzneimittel Gmbh Piroxicamholdige farmaceutiske præparater til topisk anvendelse
JP3031990B2 (ja) * 1990-10-19 2000-04-10 同仁医薬化工株式会社 消炎鎮痛クリーム剤組成物
RU2182016C2 (ru) * 1997-03-20 2002-05-10 Панацея Биотек Лтд. Спазмолитическая композиция, способ получения спазмолитической композиции
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
US7132452B2 (en) * 2003-03-10 2006-11-07 Fang-Yu Lee Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection
DE102010014290A1 (de) * 2010-04-08 2011-10-13 Hans Otto Meyer zu Spelbrink Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen

Also Published As

Publication number Publication date
JP2013523789A (ja) 2013-06-17
CN103153312B (zh) 2015-07-22
CN103153312A (zh) 2013-06-12
WO2011124366A1 (de) 2011-10-13
ES2612584T3 (es) 2017-05-17
JP6158077B6 (ja) 2018-08-29
US20140148447A1 (en) 2014-05-29
CA2795334C (en) 2015-06-09
US20130190301A1 (en) 2013-07-25
PL2374461T3 (pl) 2017-08-31
EP2374461A1 (de) 2011-10-12
JP6158077B2 (ja) 2017-07-05
EP2374461B1 (de) 2016-10-26
CA2795334A1 (en) 2011-10-13
DE102010014290A1 (de) 2011-10-13
RU2012147474A (ru) 2014-05-20
RU2555765C2 (ru) 2015-07-10

Similar Documents

Publication Publication Date Title
Ma et al. Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
US20240016767A1 (en) Method of viral inhibition
KR20210035339A (ko) 바이러스 감염을 치료하기 위한 티아졸리드 화합물
WO2021207325A1 (en) Natural extract and their components for use in mitigating acute respiratory distress syndrome
Zhao et al. Topical lipophilic epigallocatechin-3-gallate on herpes labialis: a phase II clinical trial of AverTeaX formula
DK2374461T3 (da) Piroxicam til profylaktisk og terapeutisk behandling af herpesinfektioner
JP2023123440A (ja) 合成リジンアナログ及び模倣物の抗ウイルス用途のための方法及び組成物
Pedrazini et al. L‐lysine therapy to control the clinical evolution of pityriasis rosea: clinical case report and literature review
Wald et al. Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
JP2023517639A (ja) ＳＡＲＳ－ＣｏＶ－２ウイルスによって引き起こされるウイルス感染を処置するためのジルチアゼムを含む組成物
ES2915824T3 (es) Composición farmacéutica antiviral de uso tópico
WO2015072853A1 (en) Treatment of herpes virus infection outbreaks
JP7465587B2 (ja) Ｃｏｖｉｄ－１９および関連する疾患の管理のための組成物
KR20190040185A (ko) 바이러스 감염의 치료에서 활성제로서의 키보르놀(xibornol)의 용도
Malyavin Application of HS221GI in treatment of influenza and ARVI in adults: a new approach–managing virus-induced inflammation. Results of a double-blind, randomized, placebo-controlled, multicenter clinical trial